Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is expected to experience growth in the second half of 2026, driven by increased utilization and a focus on LALs. The company's bull case scenario, which includes double-digit growth, corresponds to an estimated share price of $16, while its base case scenario has a target price of $11 based on steady recovery. While the company's 2Q26 results were disappointing, its collaboration with ALC and strong gross margins suggest potential for success in the future. Risks to this positive outlook include competition and potential financing rounds.

Bears say

RxSight is currently facing challenges with declines in utilization and margin contraction, which could lead to a decrease in revenue and profitability. These potential risks could be exacerbated by the company's reliance on a single reportable segment and its collaboration agreement with ALC, which may not be a strong indication of its PowerVision pipeline lens success. Without a significant improvement in utilization and margins, it's uncertain if RxSight can return to growth in the near future. Additionally, its valuation may be considered undemanding, but still relatively high compared to its current performance.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.